Comprehensive genomic and immune profiling (CGIP) treatment patterns and survival in non-small cell lung cancer (NSCLC) by Christina Black | Oct 18, 2022
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy by Christina Black | Sep 1, 2022
Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance by Christina Black | Jul 28, 2022
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers by Christina Black | Jul 28, 2022
Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHC by Christina Black | Jul 28, 2022